Clinical trials: Lymphoma
Diffuse Large B Cell Lymphoma, Lymphoma
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations
- Trial name
- NCT03990961
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Chicago
Lymphoma, Non-Hodgkin
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
This multicenter study will determine the response rate, the complete response rate, duration of response, time to progression, time-to-treatment failure, safety, and survival following treatment with Iodine-131 Anti-B1 Antibody…
- Trial name
- NCT00938041
- Testing
- Tositumomab and Iodine I 131 Tositumomab
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Lymphoma
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or haploidentical stem cell transplant.
- Trial name
- NCT02169505
- Testing
- Brentuximab Vedotin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term…
- Conditions
- Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
- Trial name
- NCT00096460
- Testing
- Cyclophosphamide and Rituximab, Filgrastim, Chemotherapy or Radiation therapy
- Where
- 30 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
This phase II trial studies the side effects and how well bortezomib and vorinostat work in treating patients with non-Hodgkin lymphoma (NHL) after patients' own stem cell (autologous) transplant.
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00992446
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Large B Cell Lymphoma
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
This is a phase I/II open label, multi-center study of azacytidine in combination with standard RCHOP therapy in patients with DLBCL.
- Trial name
- NCT01004991
- Testing
- rituximab, cyclophosphamide, vincristine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Follicular Lymphoma
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
The goal of this clinical research study is to learn if the combination of bendamustine hydrochloride, mitoxantrone, and rituximab can help to control follicular lymphoma. The safety of this drug combination will also be studied.
- Trial name
- NCT00901927
- Testing
- Bendamustine, Mitoxantrone, Rituximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
- Trial name
- ELARA (NCT03568461)
- Testing
- tisagenlecleucel
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 98 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with…
- Trial name
- NCT03738423
- Testing
- REGN3500
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 129 people
- Sponsor
- Regeneron Pharmaceuticals
Mantle Cell Lymphoma
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT01776840
- Testing
- Bendamustine, Rituximab, Ibrutinib
- Where
- 201 sites in United States, Argentina and 26 more
- Volunteers
- 523 people
- Sponsor
- Janssen Research & Development, LLC
Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia
HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma.
- Conditions
- Refractory B-Lineage Leukemia, Relapsed B-Lineage Leukemia, Refractory B-Lineage Lymphoma, Relapsed B-Lineage Lymphoma
- Trial name
- NCT02370160
- Testing
- DT2219ARL
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-Cell Acute Lymphoblastic Leukemia, Adult
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL (B-ALL).
- Trial name
- NCT03160079
- Testing
- blinatumomab, pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Diego
Lymphoma
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory…
- Trial name
- NCT00070291
- Testing
- cyclosporine
- Where
- 23 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00107380
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 86 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Hematologic Malignancy, Malignant Lymphoma
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.
- Trial name
- NCT01324323
- Testing
- Romidepsin, Rifampin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Celgene
Follicular Low Grade Non-Hodgkin's Lymphoma
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
This is a Phase 1/2 open label trial of G100 in participants with low grade Non-Hodgkin's Lymphoma (NHL). G100 is composed of glucopranosyl lipid A in a stable emulsion and is a potent TLR4 (toll-like receptor-4) agonist.
- Trial name
- NCT02501473
- Testing
- G100, Pembrolizumab, Rituximab
- Volunteers
- 52 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia
Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This phase II trial studies how well ruxolitinib phosphate works in treating patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
- Trial name
- NCT03041636
- Testing
- Ruxolitinib, Ruxolitinib Phosphate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Shoulder Injuries, Musculoskeletal Injury
Shoulder Instability in Children: Muscle Activity and Movement
The aim of this study is to identify factors responsible for recurrent shoulder instability in children. Shoulder instability, i.e.
- Conditions
- Shoulder Injuries, Musculoskeletal Injury, Pediatric ALL, Dislocation, Shoulder
- Trial name
- NCT04311216
- Testing
- 3D movement analysis with surface electromyography
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
Lymphoma
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma.
- Trial name
- NCT01609010
- Testing
- rituximab, interferon-a-2a
- Where
- 31 sites in Denmark, Norway and 1 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.